Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 12:46 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1681–1704 of 54,961 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Interventions: Siltuximab, Spartalizumab; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Small Cell Lung Cancer
Interventions: Tiragolumab, Atezolizumab, Carboplatin, Etoposide, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 18
States / cities: Lone Tree, Colorado • Washington D.C., District of Columbia • Fort Myers, Florida + 15 more

Conditions: Prostate Cancer
Interventions: doxorubicin hydrochloride, estramustine phosphate sodium, drug resistance inhibition treatment; Drug · Procedure
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2013
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
Interventions: ATTO-3712, Placebo; Drug
Lead sponsor: Attovia Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 9
States / cities: Encinitas, California • Fountain Valley, California • Huntington Beach, California + 6 more

Conditions: Phenylketonurias
Interventions: PKU Sphere; Dietary Supplement
Lead sponsor: Vitaflo International, Ltd; Industry
Eligibility: 3 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Heart Failure, Congestive
Interventions: DITPA (3,5-diiodothyropropionic acid), Placebo; Drug
Lead sponsor: Titan Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 22
States / cities: Huntsville, Alabama • Peoria, Arizona • Tucson, Arizona + 18 more

Conditions: Schizophrenia
Interventions: Iclepertin, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 609 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 24
States / cities: Anaheim, California • Culver City, California • Los Angeles, California + 19 more

Conditions: CD30-Positive Neoplastic Cells Present, Malignant Mesothelioma
Interventions: Brentuximab Vedotin, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Systemic Lupus Erythematosus
Interventions: Telitacicept, Placebo; Biological · Drug
Lead sponsor: Vor Biopharma; Industry
Eligibility: 12 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 4
States / cities: Hemet, California • Menifee, California • Rockford, Illinois + 1 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Multigated Acquisition Scan, Osimertinib, Radiologic Examination; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Substance Use Disorder (SUD)
Interventions: none, there is no intervention in this study; Other
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Letermovir; Procedure · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 18 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 33
States / cities: Birmingham, Alabama • Oakland, California • San Francisco, California + 28 more

Conditions: Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer, Sarcoma
Interventions: paclitaxel, pegylated liposomal doxorubicin hydrochloride; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: Up to 120 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 5
States / cities: New York, New York • The Bronx, New York • Valhalla, New York

Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions: Best Practice, Medical Chart Review; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 229 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: bryostatin 1, paclitaxel; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2004
U.S. locations: 2
States / cities: New York, New York • The Bronx, New York

Conditions: Type 2 Diabetes, Healthy (Controls)
Interventions: Not applicable- observational study; Other
Lead sponsor: Guardian Research Network, Inc.; Other
Eligibility: 40 Years to 70 Years
Enrollment: 1,200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Orangeburg, South Carolina • Walhalla, South Carolina

Conditions: Pneumonia, Pneumococcal, Vaccine
Interventions: Pneumococcal Vaccine Education; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 64 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Wilkes-Barre, Pennsylvania

Conditions: Photorefractive Keratectomy
Interventions: nepafenac 0.1%, ketorolac 0.4%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Crohn's Disease
Interventions: 4-Aminosalicylic acid extended release granules; Drug
Lead sponsor: Jacobus Pharmaceutical; Industry
Eligibility: 2 Years to 18 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 5
States / cities: Los Angeles, California • San Francisco, California • Atlanta, Georgia + 2 more

Conditions: Lymphoma
Interventions: Patient-specific dosimetry, conventional dosimetry; Device
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or More of Peripheral Blood White Cells, CD22 Positive, Lymphoblasts 20 Percent or More of Bone Marrow Nucleated Cells, Lymphoblasts 20 Percent or More of Peripheral Blood White Cells, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia
Interventions: Inotuzumab Ozogamicin, Quality-of-Life Assessment, Vincristine Sulfate Liposome; Biological · Other · Drug
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Chronic Hepatitis B Virus
Interventions: Stop NA therapy; Other
Lead sponsor: California Pacific Medical Center Research Institute; Other
Eligibility: 18 Years to 67 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 2
States / cities: San Francisco, California

Conditions: COPD
Interventions: AQX-1125, Placebo; Drug
Lead sponsor: Aquinox Pharmaceuticals (Canada) Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Melanoma (Skin)
Interventions: dendritic cell-MART-1 peptide vaccine, gp100 antigen, therapeutic tumor infiltrating lymphocytes, tyrosinase peptide; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic Cancer

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Doxorubicin Plus Estramustine in Treating Patients With Metastatic Prostate Cancer

Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis

Evaluation of PKU Sphere

Study of DITPA in Patients With Congestive Heart Failure

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery

A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Identifying Substance Use Consequences

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Combination Chemotherapy in Treating Patients With Endometrial Cancer, Fallopian Tube Cancer, or Sarcoma of the Female Reproductive Tract

Perioperative Care in the Cancer Patient -1, ARCA-1 Study

Bryostatin 1 Plus Paclitaxel in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer or Stomach Cancer

Specimen and Data Collection in South Carolina Medicaid-Enrolled Patients With Type 2 Diabetes (T2D) and Metabolically Healthy Controls

Pneumonia Vaccine Education Intervention Study

A Comparison of Topical Nepafenac to Placebo in Corneal Epithelial Healing Times and Postoperative Pain Relief

High Dose Oral 4-Aminosalicylic Acid (PASER®) to Control Acute Flares of Mild to Moderate Crohn's Disease in Children

Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma

Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia

The Hepatitis B e-Antigen Negative Disease - Directly Offered Study of Treatment Withdrawal in Patients With e-Antigen Negative Chronic HBV Infection (BeNEG-DO).

Efficacy and Safety of AQX-1125 in Unstable COPD

Vaccine Therapy in Treating Patients With Stage IV Melanoma